[go: up one dir, main page]

WO2018165929A1 - 一种双miRNA抑制表达载体及其构建方法和应用 - Google Patents

一种双miRNA抑制表达载体及其构建方法和应用 Download PDF

Info

Publication number
WO2018165929A1
WO2018165929A1 PCT/CN2017/076860 CN2017076860W WO2018165929A1 WO 2018165929 A1 WO2018165929 A1 WO 2018165929A1 CN 2017076860 W CN2017076860 W CN 2017076860W WO 2018165929 A1 WO2018165929 A1 WO 2018165929A1
Authority
WO
WIPO (PCT)
Prior art keywords
mir
tud
sequence
mirna
expression vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2017/076860
Other languages
English (en)
French (fr)
Inventor
毛吉炎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Biocan Technologies Co Ltd
Original Assignee
Shenzhen Biocan Technologies Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Biocan Technologies Co Ltd filed Critical Shenzhen Biocan Technologies Co Ltd
Priority to PCT/CN2017/076860 priority Critical patent/WO2018165929A1/zh
Publication of WO2018165929A1 publication Critical patent/WO2018165929A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Definitions

  • Double miRNA suppression expression vector construction method and application thereof
  • the present invention relates to the field of molecular biology, and in particular to a dual miRNA suppression expression vector and a construction method and application thereof.
  • RNA is an important substance in living organisms and plays various functions in life activities. RNA can be classified into messenger RNA (mRNA) and non-coding RNA (ncRNA) depending on whether the protein is encoded or not. Small RNA (small
  • RNA is an important class of ncRNAs. miRNAs are endogenous small RNAs in organisms that are typically 20-24 nt in length. The miRNA is part of the pri-miRNA (primary RNA) and is initially expressed in the nucleus by RNA polymerase ⁇ . The mature miRNA acts as a guiding molecule, binds to the target gene mRNA according to the principle of base pairing, and directs the silencing complex (RISC) to degrade mRNA or hinder its translation, thereby exerting a negative regulation effect on the expression of the target gene.
  • RISC silencing complex
  • miR-140 can inhibit the proliferation and invasion and metastasis of hepatocellular carcinoma by targeting TG FBR1 and other gene expression.
  • miR-140 is highly expressed in articular cartilage and plays a crucial role in the pathogenesis of osteoarthritis.
  • miR-424 is a miRNA discovered in recent years.
  • miR-424 acts on target genes in a variety of tumors and participates in the signal pathway of target gene regulation, thereby affecting the biological effects and development of tumor cells, playing a tumor-like, tumor-suppressing
  • the role of genes, or promote, inhibit tumor invasion and metastasis have shown that miR-424 is a multifunctional miRNA, which is associated with cell invasion and metastasis of cervical cancer, pancreatic cancer, etc.; it is associated with the expression of inflammatory factors such as IL-6 and TNF-oc; since the miR-424 promoter region has CpG islands It is also associated with methylation-induced gene silencing.
  • MiRNA functional studies usually require the use of miRNA silencing technology, mainly including anti-miR, antago miR, miRNA
  • Tough Decoy RNA is a novel miRNA-inhibiting miRNA that inhibits miRNA by introducing double-stranded RNA to target miRNAs. Because the inserted RNA is double-stranded and has a secondary structure of stem-loops, it is resistant to intracellular nuclease degradation and inhibits miRNAs in a long-term, stable, and efficient manner.
  • the technical problem to be solved by the present invention is to provide a dual miRNA suppression expression vector which is simple in structure, low in cost and simple in operation.
  • a Tud RNA targeting a dual miRNA the nucleotide sequence of which is shown in SEQ ID NO: 1 in the Sequence Listing.
  • a dual miRNA-inhibiting expression vector comprising the sequence of the invention SEQ ID NO: 1.
  • the double miRNA-inhibiting expression vector can inhibit the expression of miR-140 and miR-424 by transforming Hela cells.
  • a method for constructing a dual miRNA suppression expression vector according to the present invention comprises the following steps:
  • the synthesized sequence is two complementary single-stranded DNAs.
  • the two single-stranded DNAs were dissolved in ddH 2 0, mixed in an equimolar ratio, treated at 95 ° C for 5 min, and then allowed to cool to room temperature at room temperature.
  • the digested vector was recovered using the MinElute Reaction Cleanup Kit, and the TuD obtained in the previous step was further treated with T4 DNA ligase.
  • RNA sequence was ligated into the vector pLKO.l-puro to form the recombinant vector pLKO-TuD-140-424, and finally the ligation product was transformed into competent E. coli Stbl3 and applied to the ampicillin-containing LB medium. Plate, culture at 37 °C for 14 h. Single colonies were picked and sequenced. The bacteria with the correct sequencing were expanded and extracted with a small amount of extraction kit without endotoxin plasmid. The extracted plasmid was the plasmid of the homologous interference pLKO-T uD-140-424 required by the present invention.
  • the homologous interference miR-140 and miR-424 TuD RNA sequences designed by the present invention have a stem-loop structure and are not easily degraded, and the double-stranded Tud RNA has higher binding efficiency than the currently used single-stranded miRNA sponge. And the same target for two targets, can better achieve the interference of two miRNAs, improve the efficiency of miRNA function research.
  • Figure 1 shows the miRNA expression levels of 16HBE cells and TuD-140-424 cells, wherein a. miR-140 expression, b. miR-424 expression.
  • the lentiviral plasmid pLKO.l-puro vector used in the present invention was purchased from Addgene; the human bronchial epithelial cells (16HBE cell strain) used in the present invention were purchased from ATCC, USA.
  • TuD RNA design sequence Based on the TuD RNA design sequence and the sequence information of miR-140 and miR-424 provided in miRBase, a TuD RNA oligonucleotide sequence targeting miR-140 and miR-424 was designed, and its sequence is SEQ ID NO:
  • the synthesized sequence is two complementary single stranded DNAs.
  • the two single-stranded DNAs were dissolved in ddH 2 0, mixed in an equimolar ratio, treated at 95 ° C for 5 min, and allowed to stand at room temperature to allow them to naturally cool to room temperature.
  • Example 3 Construction of recombinant pLKO-Tud-140-424 lentiviral recombinant vector
  • the vector pLK0.1-puro was extracted and digested with Age I and Eco RI for 16 h, and the digested vector was recovered with MinElute Reaction Cleanup Kit, and then T4 DNA was used.
  • RNA sequence was ligated into the vector pLKO.l-puro to form the recombinant vector pLKO-Tud-140-424, and finally the ligation product was transformed into competent E. coli Stbl3 and plated onto a plate containing ampicillin LB medium. Incubate at 37 °C for 14 h. Single colonies were picked and sequenced. The correct sequencing bacteria were expanded and extracted with a small amount of endotoxin-free extraction kit. The extracted plasmid was the plasmid of the same interference interference pLKO-T uD-140-424 required by the present invention.
  • 16HBE cells were seeded in 6-well plates at 1,000,000 cells per well, and after 18 hours, the cell density was approximately 60%, using Lipfectamine.
  • the pLKO-TuD-140-424 plasmid was transduced into 16HBE cells and culture continued.
  • the cells were cultured for 3 days in DMEM medium containing 1.0 g/ml puromycin, and the cell line was screened as TuD-140-424 cell line.
  • the homologous interference miR-140 and miR-424 TuD RNA sequences designed by the present invention have a stem-loop structure and are not easily degraded, and the double-stranded Tud RNA has higher binding efficiency than the commonly used single-stranded miRNA sponge. And the same target for two targets, can better achieve the interference of two miRNAs, improve miRNA work

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

提供了一种双miRNA抑制表达载体及其构建方法和应用。该双miRNA抑制表达载体的构建方法是将靶向miR140和miR-424的Tud RNA连接到pLKO.1-puro克隆载体上，获得双miRNA抑制表达载体pLKO-Tud-140-424。所述双miRNA抑制表达载体起到抑制has-miR-140和has-miR-424活性的作用。

Description

一种双 miRNA抑制表达载体及其构建方法和应用 技术领域
[0001] 本发明涉及分子生物学领域， 特别是涉及一种双 miRNA抑制表达载体及其构建 方法和应用。
背景技术
RNA是生物体内一种重要物质， 在生命活动中发挥着各种各样的功能。 根据是 否编码蛋白质， RNA可分为信使 RNA (messagerRNA, mRNA) 和非编码 RNA (non-coding RNA, ncRNA) 。 小 RNA (small
RNA, smRNA) 是一类重要的 ncRNA。 miRNA是生物体内一种内源性小 RNA， 长度一般为 20-24nt。 miRNA是 pri-miRNA (primaryRNA) 的一部分， 最初在细 胞核中由 RNA聚合酶 Π转录表达。 成熟的 miRNA作为引导性分子， 根据碱基配对 原则与靶基因 mRNA结合， 引导沉默复合体 （RISC) 降解 mRNA或阻碍其翻译 ， 从而发挥对靶标基因表达的负调控作用。
miR- 140与多种疾病的发生发展密切相关， 如骨、 关节疾病， 肝脏疾病， 垂体 腺瘤， 睾丸发育， 头颈部肿瘤， 卵巢与乳腺疾病等。 miR-140能通过靶向调节 TG FBR1等基因表达抑制肝细胞癌增殖和侵袭转移， miR-140特异性高表达于关节软 骨中， 并在骨关节炎的发病机制中发挥至关重要的作用； miR-424是近年来发现 的一个 miRNA, 其在多种肿瘤中通过作用于靶基因， 参与靶基因调控的信号通 路， 从而影响肿瘤细胞生物学效应和发生发展， 发挥类似于癌基因、 抑癌基因 的作用， 或促进、 抑制肿瘤的侵袭转移。 有研究表明 miR-424是多功能 miRNA, 它与宫颈癌， 胰腺癌等细胞侵袭转移相关； 与炎性因子如 IL-6、 TNF-oc的表达相 关； 由于 miR-424启动子区域具有 CpG岛， 它与甲基化诱导的基因沉默也相关。 通过控制 miR-140和 miR-424的表达， 同吋与其他药物协同作用， 能为治疗癌症 提供新的表观遗传思路。
技术问题
[0004] MiRNA的功能研究通常需要用到 miRNA沉默技术， 主要包括 anti-miR， antago miR, miRNA
sponge等， 这些技术均属于瞬吋转染技术， 无法保持对目的 miRNA的长期稳定 沉默， 沉默效果远未达到最优。
[0005] Tough Decoy RNA (Tud RNA) 是一种新幵发出的 miRNA抑制手段， 其通过引 入双链 RNA对目标 miRNA进行吸附， 达到抑制 miRNA的目的。 由于弓 |入的 RNA 为双链并且带有茎环的二级结构， 因此其够抵抗胞内核酸酶的降解， 能长期、 稳定和高效地抑制 miRNA。
问题的解决方案
技术解决方案
[0006] 本发明要解决的技术问题是提供一种结构简单、 成本低、 操作简便的双 miRNA 抑制表达载体。
[0007] 一种靶向双 miRNA的 Tud RNA, 其核苷酸序列如序列表中 SEQ ID NO: 1所示。
[0008] 一种双 miRNA抑制表达载体， 其包括本发明所述的序列 SEQ ID N0:1。
[0009] 本发明所述双 miRNA抑制表达载体在肿瘤治疗研究中的应用， 所述双 miRNA 抑制表达载体转化 Hela细胞后能同吋抑制 miR-140和 miR-424的表达。
[0010] 一种本发明所述的双 miRNA抑制表达载体的构建方法， 包括如下步骤：
[0011] (1) 根据 miR- 140和 miR-424序列以及 Tud RNA技术原理， 设计权利要求 1所 述的靶向双 miRNA的 Tud RNA Seql， 所述 miR- 140和 miR-424序列的核苷酸序列 分别如序列表中 SEQ ID N0:2和 SEQ ID N0:3所示， 所述 Seql序列的核苷酸序 列如序列表 SEQ ID NO: 1所示， 并委托上海生工进行合成。
[0012] (2) 合成好的序列是两条互补的单链 DNA。 将两条单链 DNA溶解于 ddH 20中 ， 按照等摩尔比混合后， 95°C处理 5 min， 再将其置于室温使其自然冷却至室温
[0013] (3) 提取载体 pLK0.1-puro， 使用 Age I和 Eco RI酶双酶切处理 1
h后， 用 MinElute Reaction Cleanup Kit回收酶切后的载体， 再用 T4 DNA连接酶将 上一步得到的 TuD
RNA序列连接到载体 pLKO.l-puro中， 形成重组载体 pLKO-TuD- 140-424， 最后将 连接产物转化到感受态大肠杆菌 Stbl3中， 并涂布到含氨苄青霉素 LB培养基的平 板上， 37 °C培养 14 h。 挑取单菌落并进行测序。 取测序正确的菌扩大培养并用无 内毒素质粒小量提取试剂盒提取， 提取的质粒为本发明所需的同吋干扰 pLKO-T uD- 140-424的质粒。
发明的有益效果
有益效果
[0014] 本发明设计的同吋干扰 miR-140和 miR-424 TuD RNA序列带有茎环结构， 不容 易降解， 双链的 Tud RNA相对目前常用的单链的 miRNA sponge, 其结合效率更 高， 并且同吋针对两个靶点， 能较好地实现两个 miRNA的干扰， 提高 miRNA功 能研究的效率。
对附图的简要说明
附图说明
[0015] 图 1 16HBE细胞与 TuD-140-424细胞的 miRNA表达水平情况， 其中， a. miR-140 的表达情况， b. miR-424的表达情况。
实施该发明的最佳实施例
本发明的最佳实施方式
[0016] 根据下述实施例， 可以更好地理解本发明。 然而， 本领域的技术人员容易理解
， 实施例所描述的具体的物料配比、 工艺条件及其结果仅用于说明本发明， 而 不应当也不会限制权利要求书中所详细描述的本发明。
[0017] 本发明所使用的慢病毒质粒 pLKO.l-puro载体购自 Addgene; 本发明所使用的人 支气管上皮细胞 （16HBE细胞株） 购自美国 ATCC。
[0018] 实施例一靶向 miR-140和 miR-424a的 TuD RNA的设计与合成
[0019] 根据 TuD RNA设计序列和 miRBase中提供的 miR-140和 miR-424的序列信息， 设 计出同吋针对 miR- 140和 miR-424的 TuD RNA寡核苷酸序列， 其序列如 SEQ ID
ΝΟ:1所示， 委托上海生工以基因合成的方式合成。
[0020] 实施例二序列的退火
[0021] 合成好的序列是两条互补的单链 DNA。 将两条单链 DNA溶解于 ddH 20中， 按 照等摩尔比混合后， 95°C处理 5 min， 再将其置于室温使其自然冷却至室温。 [0022] 实施例三重组 pLKO-Tud-140-424慢病毒重组载体的构建
[0023] 提取载体 pLK0.1-puro， 使用 Age I和 Eco RI酶双酶切处理 16 h后， 用 MinElute Reaction Cleanup Kit回收酶切后的载体， 再用 T4 DNA
连接酶将上一步得到的 TuD
RNA序列连接到载体 pLKO.l-puro中， 形成重组载体 pLKO-Tud- 140-424， 最后将 连接产物转化到感受态大肠杆菌 Stbl3中， 并涂布到含氨苄青霉素 LB培养基的平 板上， 37 °C培养 14 h。 挑取单菌落并进行测序。 取测序正确的菌扩大培养并用无 内毒素质粒小量提取试剂盒提取， 提取的质粒为本发明所需的同吋干扰 pLKO-T uD- 140-424的质粒。
[0024] 实施例四 pLKO-TuD-140-424的质粒 16HBE细胞
[0025] 接种 16HBE细胞于 6孔板中， 每孔 1000000个细胞， 18h后细胞密度约为 60% ， 用 Lipfectamine
2000将 pLKO-TuD-140-424质粒转导至 16HBE细胞中， 继续培养 48
h后， 更换含 1.0 g/ml嘌呤霉素的 DMEM培养基筛选培养 3 d， 筛选获得的细胞株 命名为 TuD- 140-424细胞株。
[0026] 实施例五荧光定量 PCR检测 miRNA的表达水平变化
[0027] 分别接种正常 16HBE细胞、 TuD- 140-424细胞至 6孔板， 培养细胞约 24 h后至融 合度 80%。 用 miRcute miRNA提取分离试剂盒提取这些细胞的 miRNA, 逆转录得 到相应的 cDNA。 取 2种细胞的 cDNA各 2
为模板， 荧光定量 PCR分别检测 miR-140和 miR-424表达水平的变化， 实验重 复 3次， 每孔设置 3个平行样，以 snord
44作为内参。 结果如图 1所示， 可以看到与 TuD-140-424细胞的 miR-140的表达水 平比 16HBE细胞低 57%， miR-424的表达水平比 16HBE细胞低 62%， 差异有统计 学意义 （ρ<0.01) ， 说明 TuD- 140-424细胞株构建成功。
工业实用性
[0028] 本发明设计的同吋干扰 miR-140和 miR-424 TuD RNA序列带有茎环结构， 不容 易降解， 双链的 Tud RNA相对目前常用的单链的 miRNA sponge, 其结合效率更 高， 并且同吋针对两个靶点， 能较好地实现两个 miRNA的干扰， 提高 miRNA功
Figure imgf000006_0001

Claims

权利要求书
[权利要求 1] 一种靶向双 miRNA的 Tud RNA, 其特征在于： 其核苷酸序列如序列 表 SEQ ID NO:l所示。
[权利要求 2] —种双 miRNA抑制表达载体， 其特征在于： 其包括权利要求 1所述的 序列。
[权利要求 3] 权利要求 2所述双 miRNA抑制表达载体在肿瘤治疗研究中的应用， 所 述双 miRNA抑制表达载体同吋抑制人源 miR-140和 miR-424的表达。
[权利要求 4] 一种权利要求 2所述的双 miRNA抑制表达载体的构建方法， 其特征在 于： 包括如下步骤：
( 1 ) 根据 miR- 140和 miR-424序列以及 Tud RNA技术原理， 设计权利 要求 1所述的靶向双 miRNA的 Tud RNA Seql， 所述 miR- 140和 miR-424序列的核苷酸序列分别如序列表中 SEQ ID NO:2 和 SEQ ID NO:3所示， 所述 Seql序列的核苷酸序列如序列表 SEQ ID ΝΟ:1所示， 并委托上海生工进行合成。
(2) 合成好的序列是两条互补的单链 DNA。 将两条单链 DNA溶解于 ddH 20中， 按照等摩尔比混合后， 95°C处理 5 min， 再将其置于室温 使其自然冷却至室温。
(3) 提取载体 pLK0.1-puro， 使用 Age I和 Eco RI酶双酶切处理 1 h后
， 回收酶切后的载体， 再用 T4 DNA连接酶将上一步得到的 TuD RNA 序列连接到载体 pLKO.l-puro中， 形成重组载体 pLKO-TuD- 140-424， 最后将连接产物转化到感受态大肠杆菌 Stbl3中， 并涂布到含氨苄青 霉素 LB培养基的平板上， 37 °C培养 14 h。 挑取单菌落并进行测序。 取测序正确的菌扩大培养并用无内毒素质粒小量提取试剂盒提取， 提 取的质粒为本发明所需的同吋干扰 pLKO-TuD-140-424的质粒。
PCT/CN2017/076860 2017-03-15 2017-03-15 一种双miRNA抑制表达载体及其构建方法和应用 Ceased WO2018165929A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/076860 WO2018165929A1 (zh) 2017-03-15 2017-03-15 一种双miRNA抑制表达载体及其构建方法和应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/076860 WO2018165929A1 (zh) 2017-03-15 2017-03-15 一种双miRNA抑制表达载体及其构建方法和应用

Publications (1)

Publication Number Publication Date
WO2018165929A1 true WO2018165929A1 (zh) 2018-09-20

Family

ID=63522734

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/076860 Ceased WO2018165929A1 (zh) 2017-03-15 2017-03-15 一种双miRNA抑制表达载体及其构建方法和应用

Country Status (1)

Country Link
WO (1) WO2018165929A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110724712A (zh) * 2019-10-09 2020-01-24 重庆医科大学附属第一医院 一种miRNA海绵表达载体的构建方法及其应用
WO2021202333A1 (en) * 2020-03-30 2021-10-07 Greffex, Inc. Enhancement of the production of adenovirus-based genetransfer vectors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103623425A (zh) * 2012-08-27 2014-03-12 苏州圣诺生物医药技术有限公司 应用双靶标拮抗寡核酸抑制新血管增生疾病的药物
CN105457042A (zh) * 2015-12-23 2016-04-06 深圳市疾病预防控制中心 miR-34a沉默表达重组载体及其应用
WO2016091747A1 (en) * 2014-12-09 2016-06-16 Pierfrancesco Tassone Inhibitors of mir-17-92 cluster for anti-tumor activity in multiple myeloma and other malignancies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103623425A (zh) * 2012-08-27 2014-03-12 苏州圣诺生物医药技术有限公司 应用双靶标拮抗寡核酸抑制新血管增生疾病的药物
WO2016091747A1 (en) * 2014-12-09 2016-06-16 Pierfrancesco Tassone Inhibitors of mir-17-92 cluster for anti-tumor activity in multiple myeloma and other malignancies
CN105457042A (zh) * 2015-12-23 2016-04-06 深圳市疾病预防控制中心 miR-34a沉默表达重组载体及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAKESHI HARAGUCHI: "Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells", NUCLEIC ACIDS RESEARCH, vol. 37, no. 6, 17 February 2009 (2009-02-17), pages 6, XP055538616, ISSN: 0305-1048 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110724712A (zh) * 2019-10-09 2020-01-24 重庆医科大学附属第一医院 一种miRNA海绵表达载体的构建方法及其应用
WO2021202333A1 (en) * 2020-03-30 2021-10-07 Greffex, Inc. Enhancement of the production of adenovirus-based genetransfer vectors
CN115803439A (zh) * 2020-03-30 2023-03-14 格雷菲克斯公司 增强基于腺病毒的基因转移载体的生产

Similar Documents

Publication Publication Date Title
EP3778892A1 (en) Novel small activating rna
CN106032532A (zh) 一种小激活rna及其制备方法和应用
WO2018165929A1 (zh) 一种双miRNA抑制表达载体及其构建方法和应用
Sun et al. Construction of lentivirus-based inhibitor of hsa-microRNA-338-3p with specific secondary structure
WO2016145608A1 (zh) 一种小激活rna及其制备方法和应用
WO2017214952A1 (zh) 特异抑制人 miRNA-185 表达的慢病毒载体的构建及其应用
WO2018170621A1 (zh) 降低miR-148a和miR-424表达的载体及其应用
WO2017214948A1 (zh) 一种敲低人 miRNA-148a 表达的慢病毒载体的构建及其应用
WO2018170620A1 (zh) 一种同时敲减两种miRNA表达的载体
CN102229928B (zh) 人rbbp6基因的小干扰rna及其应用
WO2018170619A1 (zh) 抑制双miRNA表达的载体及其应用
WO2017214953A1 (zh) 一种特异抑制人 miRNA-424 表达的慢病毒载体的构建及其应用
WO2017214950A1 (zh) 敲低人miRNA-140表达的慢病毒载体的构建及其应用
CN101831461A (zh) 一种人小RNA-148a表达载体及应用
WO2017214951A1 (zh) 一种抑制人miRNA-152表达的慢病毒载体的构建及其应用
WO2017219166A1 (zh) 一种同时抑制双 miRNA 表达的慢病毒载体及其应用
WO2017219167A1 (zh) 特异抑制双 miRNA 表达的慢病毒载体的构建及其应用
WO2017219172A1 (zh) 敲低 miRNA-140 和 miR-152 表达的慢病毒载体的构建及其应用
WO2017219168A1 (zh) 一种 miRNA-29a 和 miR-152 表达敲低的慢病毒载体及其应用
WO2017219170A1 (zh) 特异抑制人 miRNA-29a 和 miR-424 表达的慢病毒载体的构建及其应用
WO2017214949A1 (zh) 一种抑制 miRNA-29a 表达的慢病毒载体的构建及其应用
WO2018170623A1 (zh) 降低微小rna-152和微小rna-424表达的方法
WO2017219169A1 (zh) 一种抑制 miRNA-29a 和 miR-185 表达的慢病毒载体及其应用
CN106591311B (zh) 核酸及其用途
WO2018170750A1 (zh) 小 RNA-29a 、 148a 和 152 的表达抑制的 Tud RNA 及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17901206

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17901206

Country of ref document: EP

Kind code of ref document: A1